LUIS CURBELO CUNILL: Open Payments
NPI 1750979803 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,961 in 154 payments from 16 companies in 2025. Trend: 2023 $221 · 2024 $2,067 · 2025 $2,961
Food & beverage: $2,851Education: $109
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $387 |
| Teva Pharmaceuticals USA, Inc. | 18 | $362 |
| Otsuka America Pharmaceutical, Inc. | 17 | $347 |
| Janssen Pharmaceuticals, Inc | 17 | $268 |
| Alkermes, Inc. | 15 | $263 |
| Neurocrine BioSciences, Inc. | 12 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $201 |
| Almatica Pharma LLC | 9 | $190 |
| Axsome Therapeutics, Inc. | 9 | $173 |
| Lundbeck LLC | 6 | $155 |
Products named: CAPLYTA, REXULTI, ARISTADA, INGREZZA, INVEGA SUSTENNA, TRINTELLIX, LOREEV XR, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
